ArticleFrontiers in oncology2026
Integrating intratumoral and peritumoral radiomics with deep transfer learning from multiparametric MRI for preoperative prediction of HER2 status in breast cancer: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop and validate a combined model integrating intratumoral and peritumoral radiomics features, deep transfer learning features from multiparametric MRI (DCE-MRI, T2WI, and DWI), and clinical indicators, and to evaluate its diagnostic performance and clinical utility for preoperative prediction of HER2 expression status in breast cancer. Methods: We collected data from 411 breast cancer patients from three centers retrospectively (training set: 212; internal validation set: 91; external test sets: 50 and 58). Multiparametric MRI (DCE/T2WI/DWI) was acquired. This study extracted manually constructed radiomics features and deep transfer-learning features based on ResNet50 from the tumor interior and peritumoral regions using multiparametric MRI. Through multiple feature-selection steps, such as intraclass correlation coefficient calculation, Spearman correlation testing, and LASSO logistic regression, a fusion feature set of deep learning and radiomics (DLR) was constructed. Finally, the DLR feature set was combined with independent clinical predictors to establish a combined prediction model. The model performance was evaluated using receiver operating characteristic curves, calibration curves, and decision curve analysis, and visual interpretability analysis was conducted using Grad-CAM and SHAP methods. Results: The combined model had the best accuracy and prediction ability, with AUC values of 0.965 (95% CI: 0.939-0.990) and 0.904 (95% CI: 0.843-0.966) for the training and internal validation cohorts, respectively. In external test sets 1 and 2, it had AUCs of 0.844 (95% CI: 0.724-0.964) and 0.846 (95% CI: 0.743-0.949), respectively. Conclusions: By integrating intratumoral/peritumoral features from multiparametric MRI, radiomics, and deep transfer learning, and combining these with clinical indicators, the developed model enables precise prediction of HER2 status in breast cancer. This provides a reliable assessment tool for precision diagnosis and treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.